本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
台北2026年2月11日 /美通社/ -- 全球電腦領導品牌技嘉科技攜手 NVIDIA 推出《Resident Evil™ Requiem》遊戲套裝合作，涵蓋搭載 GeForce RTX™ 5070 以上桌機及筆電繪圖晶片的指定顯示卡、AI 電競筆電與電競主機。GeForce RTX™ 50 系列顯示卡採用 NVIDIA Blackwell 架構，透過路徑追蹤、DLSS 4 與 Reflex 等技術為玩家帶來突破性的遊戲體驗。RTX™ 50 系列顯示卡具備強大的 AI 運算能力，可為不同遊戲情境提供高擬真度的圖像；結合技嘉在各產品線導入的獨家散熱設計，讓玩家在《Resident Evil™ Requiem》中享有前所未有的流暢度與絕佳沉浸的視覺效果。 技嘉攜手 NVIDIA 推出《Resident Evil™ Requiem》遊戲套裝 強化沉浸遊戲體驗 顯示卡為影響遊戲運算的關鍵因素之一，而 GeForce RTX™ 50 系列顯示卡則透過 NVIDIA 三大核心技術提升整體遊戲表現。路徑追蹤透過模擬光線的物理行為，呈現更接近真實世界的即時 3D 視覺效果；搭配 NVIDIA 的神經渲染技術套件，DLSS 4 運用 AI 強化影像處理能力，可提升幀數、降低延遲並改善畫質；而 NVIDIA Reflex 則可進一步降低系統延遲，讓操作回饋更即時、控制更精準。 為了支援高效能的 RTX™ 50 系列顯示晶片，技嘉提供多元散熱方案以滿足不同裝機需求。其中，GeForce RTX™ 5090 與 RTX™ 5080 旗艦級水冷機種，搭載 WATERFORCE 水之力一體封閉式或開放式散熱系統，在高負載使用下能兼顧穩定的散熱效能與低溫靜音運轉表現。WINDFORCE 風之力散熱系統則導入 Hawk fan 設計與伺服器等級導熱凝膠，有效減少風阻、降低噪音並提升導熱效率。技嘉也於今年推出旗艦級 AORUS GeForce RTX™ 5090 INFINITY 顯示卡，結合最新研發 Hyperburst 散熱系統、創新的分離式 PCB 結構設計與更精巧的機身尺寸，滿足遊戲玩家及 AI 運算領域的多元需求。 本次合作亦囊括 AI 電競筆電與電競主機，AORUS MASTER 16、GIGABYTE AERO X16 與 GAMING A16 PRO AI 電競筆電搭載 GeForce RTX™ 5070 或以上筆電顯示卡，結合 WINDFORCE Infinity 散熱系統與獨家智慧 AI 夥伴 GiMATE，提供更智能的效能、工作效率與系統控制體驗。專為中高階玩家打造的 AORUS PRIME 5 與指定 PRIME 3 電競主機，具備全方位系統散熱設計與各式連接埠，提供即插即用的便利體驗。 凡於 2 月 10 日至 3 月 16 日期間購買符合資格之技嘉顯示卡、AI 電競筆電或電競主機，即可獲得將於 2 月 27 日上市的《Resident Evil™ Requiem》標準版遊戲兌換碼，並需於 4 月 16 日前完成遊戲啟用。更多活動資訊、適用資格與產品，請詳閱活動連結。
TAIPEI, Feb. 11, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, collaborates with NVIDIA for the Resident Evil™ Requiem game bundle across eligible graphics cards, desktops, and laptops powered by NVIDIA GeForce RTX™ 5070 or above GPUs or Laptop GPUs. Powered by NVIDIA Blackwell architecture, the GeForce RTX™ 50 Series GPUs bring game-changing capabilities to gamers and creators. Equipped with a massive level of AI horsepower, the RTX™ 50 Series enables new experiences and next-level graphics fidelity. Combined with GIGABYTE's cutting-edge cooling designs, the bundle aims to unleash smoother gameplay and a more immersive Resident Evil Requiem gaming experience. GIGABYTE Collaborates with NVIDIA® GeForce RTX™ for Resident Evil™ Requiem Bundle The GeForce RTX™ 50 Series GPUs leverage a trio of key technologies to elevate gameplay. Path tracing simulates the physical behavior of light to deliver photorealistic and real-time 3D graphics. Alongside NVIDIA's suite of neural rendering technologies, DLSS 4 leverages AI technologies to boost FPS, reduce latency, and enhance image quality, while NVIDIA Reflex further reduces system latency for more responsive control. For eligible graphics cards, GIGABYTE offers multiple thermal solutions tailored for different build styles and performance needs. The WATERFORCE cooling system is available in both all-in-one and water block variants for GeForce RTX™ 5090 and RTX™ 5080 models, delivering exceptional heat dissipation and silent operation during demanding workloads. The WINDFORCE air-cooling system integrates Hawk fan design and server-grade thermal conductive gel to maximize thermal efficiency. At the flagship tier, GIGABYTE introduced the AORUS GeForce RTX™ 5090 INFINITY, combining the Hyperburst cooling system, separated PCB layout, and compact dimension to redefine airflow performance and form factor footprint for elite gaming setups. The bundle also extends to eligible gaming systems, including AI gaming laptops and gaming desktops. AORUS MASTER 16, GIGABYTE AERO X16, and GAMING A16 PRO AI gaming laptops are powered by GeForce RTX™ 5070 or above Laptop GPUs with the WINDFORCE Infinity cooling system, alongside an exclusive AI agent, GiMATE, for smarter performance and system control. On the desktop side, AORUS PRIME 5 and selected PRIME 3 gaming desktops are equipped with an all-around system cooling solution and comprehensive connectivity for a plug-and-play gaming experience. Gamers who purchase eligible GIGABYTE graphics cards, AI gaming laptops, or gaming desktops between February 10 and March 16 can obtain a Resident Evil™ Requiem standard edition redeem code for game activation from February 27 to April 16. For more details, eligibility, and participating products, please visit the campaign page.
As AI moves from experimentation to cultural, economic, and organisational force, CIOs are being challenged to understand not just the technology, but its real-world impact on power, creativity, and decision-making. At Info-Tech LIVE 2026 in Brisbane, March 17 – 18, 2026, global AI leader and advisor Mark Adams will deliver a keynote designed to help IT leaders cut through hype and translate AI disruption into strategic advantage. SYDNEY, Feb. 11, 2026 /PRNewswire/ -- Artificial intelligence is reshaping industries far beyond the technology sector, influencing culture, politics, media, and leadership at unprecedented speed. At Info-Tech LIVE 2026 in Brisbane, taking place March 17 – 18, 2026, at W Brisbane, Info-Tech Research Group will welcome global AI leader and advisor Mark Adams as a featured keynote speaker for the event's second annual APAC edition. Hollywood’s AI Insider Mark Adams to Keynote Info-Tech LIVE 2026 in Brisbane Widely known as "Hollywood's AI Insider," Adams brings a rare perspective shaped by decades of operating at the intersection of Silicon Valley, global media, and the Fortune 500. He has advised more than 150 global icons and institutions, guiding leaders across entertainment, business, and government to understand and harness AI during moments of high-stakes transformation. Drawing on firsthand experience behind some of the most defining cultural and commercial moments of the modern era, Adams' keynote will explore how AI is already reshaping power, creativity, and organisational relevance, and what that means for today's CIOs. "CIOs today are facing a very different kind of AI-driven disruption, one that now shapes culture, influence, and decision-making," says George Khreish, Managing Partner at Info-Tech Research Group, APAC. "We're excited to have Mark Adams at Info-Tech LIVE 2026 in Brisbane because he offers a perspective few technology leaders ever get access to. He's worked in environments where AI decisions already carry real influence, from global brands to cultural institutions, making his insights highly relevant for today's IT leaders." A serial entrepreneur, Adams is a co-founder of VICE, which he helped scale from a counterculture publication into a multi-billion-dollar global media organisation spanning television, film, digital platforms, and creative services. He currently advises and serves on the boards of globally recognised brands, including Gymshark, Headspace, and Ocean Bottle, and continues to work with executive teams on AI-driven transformation through his "Match Point" methodology, a framework that simplifies complexity and accelerates impact. Now in its second year in the APAC region, Info-Tech LIVE 2026 in Brisbane will bring together IT leaders from across Australia, New Zealand, and the broader Asia-Pacific to engage with Info-Tech's latest research, practical frameworks, and peer insights. Hosted at W Brisbane, the event delivers a hands-on strategy conference that translates theory into execution across AI, leadership, data, and core IT capabilities. Additional sessions and speaker announcements will be released in the coming weeks. For more information about the event, please visit the Info-Tech LIVE 2026 in Brisbane page. Media Passes for Info-Tech LIVE 2026 in Brisbane Media professionals, including journalists, podcasters, and influencers, are invited to attend Info-Tech LIVE 2026 in Brisbane to gain exclusive access to research, content, and interviews with industry leaders and analysts for their audiences. Media professionals can apply for complimentary in-person passes by contacting pr@infotech.com. About Info-Tech Research Group Info-Tech Research Group is one of the world's leading and fastest-growing research and advisory firms, serving over 30,000 IT, HR, and marketing professionals around the globe. As a trusted product and service leader, the company delivers unbiased, highly relevant research and industry-leading advisory support to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide everything they need, from actionable tools to expert guidance, ensuring they deliver measurable results for their organisations. To learn more about Info-Tech's HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm's SoftwareReviews platform. Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@infotech.com. For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X. Media Contact: Sufyan Al-Hassan, PR Director, Info-Tech Research Group, salhassan@infotech.com, +1 (888) 670-8889 x2418 Photo - https://mma.prnasia.com/media2/2901602/Info_Tech_Research_Group_Global_AI_Leader_Mark_Adams_to_Keynote.jpg?p=medium600 Logo - https://mma.prnasia.com/media2/2901601/Info_Tech_Research_Group_Global_AI_Leader_Mark_Adams_to_Keynote.jpg?p=medium600
柏林2026年2月11日 /美通社/ -- Transparency International 今日發佈的《2025 年貪污感知指數 (CPI）》顯示，全球貪污問題日趨嚴重，甚至成熟的民主國家也在倒退，其領導層長期以來應對貪污的能力下滑，情況堪憂。 CPI 2025 MAP 第 31 版貪污感知指數指出，得分超過 80 分的國家，數目已從十年前的 12 個，大減至 2025 年的只剩 5 個。 向來被視為反貪污典範的民主國家，例如美國、加拿大、紐西蘭、英國、法國及瑞典，評分也呈現令人憂心的下滑趨勢。 另一令人關注的趨勢是對公民空間的打壓。 自 2012 年起，在 50 個指數顯著下跌的國家中，有 36 個國家的言論、結社與集會自由同時下滑，導致記者及公民社會難以揭露和批判貪污問題。 2025 年，年青人成為大型反貪污抗議活動的主力軍，尤其是在那些貪污感知指數排名靠後或過去十年分數停滯不前或倒退的國家。 在尼泊爾及馬達加斯加，示威民眾指責領導層濫權失職，既無法保障基本服務，亦未能創造經濟機會，最終導致兩國政權倒台。 Transparency International 發出警告，指出全球反貪污戰線缺乏魄力十足的政治領導，將導致國際協作乏力，世界各國內部的改革壓力也隨之鬆懈。 Transparency International 主席 François Valérian 指出：「貪污絕非不可避免。 我們深知制衡權力、造福公益之道：民主問責機制、獨立監督體系，以及自由開放的公民社會。 在某些國家正危險地漠視國際規範之際，我們在此敦促各國領袖恪守誠信、承擔責任，為全球民眾創造更美好的未來。」 Transparency International 呼籲各國政府： 通過全面執法、履行國際承諾及加強透明度、監督和問責，重振反貪污政治領導。 捍衛公民社會空間，立即停止打擊記者、非政府組織 (NGO) 及舉報人，並終止一切打壓獨立公民社會的行動。 堵塞讓貪污資金跨境流動的保密漏洞，具體措施包括加強實益擁有權資訊透明度，並規管協助資金流轉的專業中介。 歡迎聯絡機構發言人進行採訪。 請聯絡：press@transparency.org 在此查看完整報告、評分結果、調查方法、新聞稿及相關圖像！
- 在非人靈長類動物研究中，通過利用歌禮口服多肽遞送增強技術（POTENT），ASC36口服片在穩態下的絕對口服生物利用度達6%至8%。 - 在非人靈長類動物中，ASC36口服片每日一次給藥7天後，使相對基線的平均體重下降高達13.2%。ASC36片亦顯著減少了食物攝入。 - 在一項頭對頭飲食誘導肥胖（DIO）大鼠模型中，與eloralintide和petrelintide相比，ASC36實現的減重效果分別相對提升約32%和91%。 - 憑借潛在更優的口服生物利用度和療效，預計ASC36口服片的給藥劑量更低。每毫克ASC36多肽更優越的減重效果，也可能使其在規模化生產中成本更低。 - 預計將於2026年第二季度向美國食品藥品監督管理局（FDA）遞交ASC36口服片的新藥臨床試驗申請（IND）。 香港2026年2月11日 /美通社/ -- 歌禮制藥有限公司（香港聯交所代碼：1672，簡稱「歌禮」）宣布已選定其首款口服胰澱素受體激動劑多肽ASC36口服片進行臨床開發。歌禮預計將於2026年第二季度向美國食品藥品監督管理局（FDA）遞交ASC36口服片治療肥胖症的新藥臨床試驗申請（IND）。 ASC36口服片由歌禮利用其專有的口服多肽遞送增強技術（POTENT）開發而成。在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7天後，穩態下的絕對口服生物利用度（absolute oral bioavailability）[1]為8%，消除半衰期（elimination half-life）達116小時；25毫克ASC36口服片在每只動物中每日一次給藥，給藥7天後，穩態下的絕對口服生物利用度為6%，消除半衰期達167小時。ASC36口服片較長的消除半衰期（116小時至167小時），為每日一次及更低頻率的口服給藥方案提供了支持。 ASC36口服片在非人靈長類動物和飲食誘導肥胖（DIO）大鼠模型中均表現出了顯著的減重效果。在非人靈長類動物中，ASC36口服片每日一次給藥7天後，使相對基線的平均體重下降高達13.2%。ASC36片亦顯著減少了食物攝入。 在一項頭對頭DIO大鼠模型中，治療7天後，與eloralintide和petrelintide相比，ASC36實現的減重效果分別相對提升約32%和91%。 與近期獲FDA批准的一款GLP-1R激動劑多肽相比，憑借潛在更優的口服生物利用度和療效，預計ASC36口服片的給藥劑量更低。每毫克ASC36多肽更優越的減重效果，也可能使其在規模化生產中成本更低（scalability advantages in manufacturing）。 ASC36是一款利用歌禮基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）技術自主研發的胰澱素受體激動劑多肽。ASC36口服片劑由歌禮利用其專有的POTENT技術開發並優化而成，該技術用於實現口服多肽遞送。 「我們有三個關鍵的胰澱素候選藥物：口服小分子胰澱素、口服胰澱素多肽和每月一次皮下注射胰澱素多肽，ASC36口服片是其中一款重要的胰澱素激動劑，」歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示，「依托我們的三大專有技術平台，包括AISBDD、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）和POTENT，歌禮已成功構建了一個極具競爭力、差異化且多元化的產品管線組合，有望有效應對肥胖及其他代謝疾病患者多樣化的治療需求。」 [1] 絕對口服生物利用度：指與靜脈給藥相比，相同藥物在以口服方式給藥後進入全身循環（血液）的劑量百分比 關於歌禮制藥有限公司 歌禮制藥有限公司是一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。 欲了解更多信息，敬請登錄網站：www.ascletis.com。 詳情垂詢： Peter VozzoICR Healthcare443-231-0505 (美國)Peter.vozzo@icrhealthcare.com 歌禮制藥有限公司PR和IR團隊+86-181-0650-9129 (中國)pr@ascletis.comir@ascletis.com
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. - In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly. - In a head-to-head diet-induced obese (DIO) rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively. - ASC36 oral tablets are expected to utilize a lower dose due to potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing. - Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets is expected in the second quarter of 2026. HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026. ASC36 oral tablets were developed with Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT). In non-human primates (NHPs), 10 mg ASC36 oral tablet per animal dosed once daily for 7 days achieved absolute oral bioavailability[1] of 8% and elimination half-life of 116 hours at steady state; 25 mg ASC36 oral tablet per animal dosed once daily for 7 days achieved absolute oral bioavailability of 6% and elimination half-life of 167 hours at steady state. The long elimination half-life (116 hours to 167 hours) of ASC36 oral tablets supports once-daily and less frequent oral dosing. ASC36 oral tablets demonstrated significant weight loss in both NHP and diet-induced obese (DIO) rat models. In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly. In a head-to-head DIO rat model, after 7 days of treatment, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively. ASC36 oral tablets are expected to utilize a lower dose, relative to a recently FDA approved oral GLP-1R peptide agonist, due to potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing. ASC36, an amylin receptor peptide agonist, was discovered and developed in-house utilizing Ascletis' Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD). ASC36 oral tablet formulation was developed and optimized by Ascletis' POTENT technology for delivery of oral peptides. "ASC36 oral tablets is an important amylin agonist among three key amylin drug candidates, i.e. an oral small molecule amylin, an oral peptide amylin and a once-monthly subcutaneous injectable peptide amylin," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "Leveraging our three proprietary technology platforms, including AISBDD, Ultra-Long-Acting Platform (ULAP) and POTENT, Ascletis has successfully established a highly competitive, differentiated and diverse pipeline portfolio which can potentially effectively address the various treatment needs of patients with obesity and other metabolic diseases." [1] Absolute oral bioavailability: the percentage of an orally administered drug that reaches the systemic circulation (bloodstream), compared to an intravenous (IV) dose of the same drug About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit www.ascletis.com. Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.)Peter.vozzo@icrhealthcare.com Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ascletis.comir@ascletis.com
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
